AbbVie reported first-quarter 2026 net revenues of $15 billion, up 12.4% year-over-year, driven by strong growth in immunology and neuroscience products. Adjusted diluted EPS rose 7.7% to $2.65 despite a $0.41 per share impact from acquired IPR&D and milestones expenses. Key products like Skyrizi and Rinvoq showed significant revenue increases, while Humira declined. AbbVie raised its full-year 2026 adjusted EPS guidance to $14.08-$14.28, reflecting confidence in its pipeline and business fundamentals.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
